Edge Rewrite
everything Source code View original
// HTMLRewriter · presentation

This page was redesigned at the edge.

Cloudflare fetched the original article and streamed it through HTMLRewriter to apply an entirely new visual system without rebuilding the source page.

// request.cf · coarse context

A page that knows where it met you.

Only coarse request metadata is shown. This demo does not display or persist visitor IP addresses.

Country
US
Cloudflare location
CMH
Connection
HTTP/2
Language
Not provided

Ray ID: a25f94f98f69cf7c

Jump to content

// Workers AI · dad joke modeWhat did Paliroden say to its date? You're a rodent to my heart.

Add links
From Wikipedia, the free encyclopedia

Paliroden
Clinical data
Other namesSR-57667; SR57667; SR-57667B; SR57667B
Routes of
administration		Oral[1]
ATC code
  • None
Identifiers
  • 1-[2-(4-phenylphenyl)ethyl]-4-[3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-pyridine
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
ChEBI
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC26H24F3N
Molar mass407.480 g·mol−1
3D model (JSmol)
  • C1CN(CC=C1C2=CC(=CC=C2)C(F)(F)F)CCC3=CC=C(C=C3)C4=CC=CC=C4
  • InChI=1S/C26H24F3N/c27-26(28,29)25-8-4-7-24(19-25)23-14-17-30(18-15-23)16-13-20-9-11-22(12-10-20)21-5-2-1-3-6-21/h1-12,14,19H,13,15-18H2
  • Key:CNEWKIDCGDXBDE-UHFFFAOYSA-N

Paliroden (INNTooltip International Nonproprietary Name; developmental code names SR-57667 and SR-57667B) is a drug which was under development for the treatment of Alzheimer's disease and Parkinson's disease but was never marketed.[1][2] It is taken orally.[1] The exact mechanism of action of the drug does not appear to have been disclosed,[1] but it has been found to stimulate neurogenesis in preclinical research.[3] It was under development by sanofi-aventis.[1] Paliroden reached phase 2 clinical trials for Alzheimer's disease and Parkinson's disease prior to the discontinuation of its development in 2007.[1][2] It is an analogue and follow-on drug of xaliproden (SR-57746; SR-57746A), which is a serotonin 5-HT1A receptor agonist and neurogenesis stimulant that reached phase 3 trials for similar indications but also did not complete development.[4]

See also

[edit]

References

[edit]
  1. 1 2 3 4 5 6 "Paliroden". AdisInsight. 2 October 2007. Retrieved 28 July 2026.
  2. 1 2 "Delving into the Latest Updates on Paliroden with Synapse". Synapse. 4 April 2026. Retrieved 28 July 2026.
  3. ↑ Labie C, Canolle B, Chatelin S, Lafon C, Fournier J (February 2006). "Effects of paliroden (SR57667B) and xaliproden on adult brain neurogenesis". Current Alzheimer Research. 3 (1): 35–36. doi:10.2174/156720506775697070. PMID 16472201.
  4. ↑ Froestl W, Pfeifer A, Muhs A (2013). "Cognitive enhancers (nootropics). Part 3: drugs interacting with targets other than receptors or enzymes. disease-modifying drugs". Journal of Alzheimer's Disease. 34 (1): 1–114. doi:10.3233/JAD-121729. PMID 23186990. The development of many drugs interacting with neurotrophic factors was terminated. The most advanced drug, xaliproden (SR-57746A, Xaprila; sanofi), a 5-HT1A agonist and stimulator of endogenous neurotrophin synthesis, did not meet the cognition endpoints in Phase III trials in AD patients, which applies also to paliroden (SR-57667B; with a biphenyl instead of the β-naphtyl in xaliproden; sanofi, [204]). The lessons learnt from the xaliproden clinical trials were discussed [205]. The biological characterization was reviewed [206].
Retrieved from "https://en.wikipedia.org/w/index.php?title=Paliroden&oldid=1366595544"